The directors of Invictus Therapeutics Ltd (Invictus) (formerly VGI Health Technology Limited (NSX:VTL) are pleased to announce that the United States Patent and Trademarks Office (USPTO) intends to grant a patent for the ‘Transmucosal Delivery of Tocotrienols’ to its wholly-owned subsidiary Invictus Biotechnology Pty Ltd and has issued a Notice of Allowance dated 16 July

The directors of Invictus Therapeutics Ltd (Invictus) (formerly VGI Health Technology Limited (NSX:VTL) advise that the Company has been served with an Application to Wind Up the Company by Cornwalls (the Application). Click here to download the full document.

The directors of Invictus Therapeutics Ltd (Invictus) (formerly VGI Health Technology Limited (NSX:VTL)) refer to the Company’s announcements of 28 November 2025 and 23 December 2025 regarding the timetable for the share consolidation, which was approved by Shareholders at the 2025 Annual General Meeting held on 28 November 2025. Click here to download the full

The directors of Invictus Therapeutics Ltd (Invictus) (formerly VGI Health Technology Limited (NSX:VTL)) refer to the Company’s announcement of 28 November 2025 regarding the timetable for the share consolidation which was approved by Shareholders at the 2025 Annual General Meeting held on 28 November 2025. Click here to download the full document.

The Directors of Invictus Therapeutics Ltd (the Company or VTL) wish to advise that the Company, and its subsidiaries, have changed the address of the registered office and principal place of business. Click here to download the full document.

VGI Health Technology Limited (VTL or the Company) is pleased to advise that in accordance with a resolution passed by its shareholders at the Company’s 2025 Annual General Meeting on 28 November 2025, the change of Company name to Invictus Therapeutics Ltd has been processed by the Australian Securities and Investments Commission. Click here to